3D in vitro models of tumors expressing EGFR family receptors: a potent tool for studying receptor biology and targeted drug development.
Journal
Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
08
05
2018
revised:
27
07
2018
accepted:
05
09
2018
pubmed:
12
9
2018
medline:
30
7
2019
entrez:
12
9
2018
Statut:
ppublish
Résumé
Carcinomas overexpressing EGFR family receptors are of high clinical importance, because the receptors have prognostic value and are used as molecular targets for anticancer therapy. Insufficient drug efficacy necessitates further in-depth research of the receptor biology and improvement in preclinical stages of drug evaluation. Here, we review the currently used advanced 3D in vitro models of tumors, including tumor spheroids, models in natural and synthetic matrices, tumor organoids and microfluidic-based models, as a potent tool for studying EGFR biology and targeted drug development. We are especially focused on factors that affect the biology of tumor cells, causing modification in the expression and basic phosphorylation of the receptors, crosstalk with other signaling pathways and switch between downstream cascades, resulting ultimately in the resistance to antitumor agents.
Identifiants
pubmed: 30205170
pii: S1359-6446(18)30168-5
doi: 10.1016/j.drudis.2018.09.003
pii:
doi:
Substances chimiques
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Pagination
99-111Informations de copyright
Copyright © 2018 Elsevier Ltd. All rights reserved.